We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: semaglutide
MedXY News
EnglishTag

semaglutide

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Comparative Impacts of Semaglutide and Bariatric Surgery on Hepatic Steatosis and Fibrosis in Obese Patients with MASLD
Diabetes & Endocrinologybariatric surgeryhepatic fibrosis

Comparative Impacts of Semaglutide and Bariatric Surgery on Hepatic Steatosis and Fibrosis in Obese Patients with MASLD

By MedXY|Aug 29, 2026

This prospective cohort study compares semaglutide, bariatric surgery, and lifestyle therapy in obese patients with MASLD, demonstrating semaglutide and surgery improve liver steatosis and fibrosis markers better than lifestyle changes alon

Comparative Efficacy and Safety of Bofanglutide versus Semaglutide in Chinese Patients with Type 2 Diabetes: Insights from a Phase 2b Trial
Diabetes & Endocrinology
semaglutide
GLP-1 receptor agonist

Comparative Efficacy and Safety of Bofanglutide versus Semaglutide in Chinese Patients with Type 2 Diabetes: Insights from a Phase 2b Trial

By MedXY|Aug 27, 2026

This phase 2b trial evaluates bofanglutide’s efficacy and safety compared to semaglutide in Chinese patients with type 2 diabetes, showing notable HbA1c reductions and manageable gastrointestinal side effects.

Semaglutide’s Impact on Inflammation and Cardiovascular Risk in Overweight Patients: Insights from the SELECT Trial
Cardiologycardiovascular diseaseobesity

Semaglutide’s Impact on Inflammation and Cardiovascular Risk in Overweight Patients: Insights from the SELECT Trial

By MedXY|Aug 21, 2026

In the SELECT trial, semaglutide significantly lowered hsCRP levels and major cardiovascular events in patients with established atherosclerotic cardiovascular disease and overweight or obesity, suggesting inflammation reduction as a possib

Once-weekly IcoSema versus Daily Insulin Glargine U100 in Type 2 Diabetes: Evidence from the COMBINE 4 Phase 3b Trial and Related Advances
Clinical Updatessemaglutidehypoglycaemia

Once-weekly IcoSema versus Daily Insulin Glargine U100 in Type 2 Diabetes: Evidence from the COMBINE 4 Phase 3b Trial and Related Advances

By MedXY|Aug 15, 2026

COMBINE 4 demonstrated that once-weekly IcoSema (icodec+semaglutide) offers superior glycemic control, weight reduction, and reduced hypoglycemia versus daily insulin glargine U100 in insulin-naive type 2 diabetes patients, supported by com

Impact of Semaglutide Exposure on Gestational Weight Gain and Pregnancy Outcomes in Overweight and Obese Women
Diabetes & Endocrinologysemaglutideobesity

Impact of Semaglutide Exposure on Gestational Weight Gain and Pregnancy Outcomes in Overweight and Obese Women

By MedXY|Aug 18, 2026

This study investigates how semaglutide exposure before and during pregnancy affects gestational weight gain and key pregnancy outcomes in women with overweight or obesity, highlighting increased risks that may stem from treatment discontin

Efficacy and Safety of Once-Weekly Semaglutide 2.4 mg in Chinese Adults with Overweight or Obesity: Insights from the STEP 12 Trial and Regional Evidence
Clinical Updatesweight managementsemaglutide

Efficacy and Safety of Once-Weekly Semaglutide 2.4 mg in Chinese Adults with Overweight or Obesity: Insights from the STEP 12 Trial and Regional Evidence

By MedXY|Aug 11, 2026

This review synthesizes evidence from the STEP 12 trial and related studies demonstrating that once-weekly semaglutide 2.4 mg significantly reduces bodyweight and improves cardiometabolic outcomes in Chinese adults with overweight or obesit

Pooled Analysis of SELECT, FLOW, and SOUL Links Semaglutide to Reduced Kidney Outcomes
Diabetes & Endocrinologycardio-kidney-metabolic diseasesemaglutide

Pooled Analysis of SELECT, FLOW, and SOUL Links Semaglutide to Reduced Kidney Outcomes

By MedXY|Aug 8, 2026

A prespecified pooled analysis of three phase 3 trials including 30,787 participants found semaglutide reduced major kidney outcomes versus placebo, with a 16% relative risk reduction in the primary composite and a favourable safety profile across cardio-kidney-metabolic disease.

Semaglutide as an Effective Add-On Therapy in Latent Autoimmune Diabetes in Adults: Enhancing Glycemic Control and Preserving β-Cell Function
Diabetes & EndocrinologyGLP-1 receptor agonistGlycemic Control

Semaglutide as an Effective Add-On Therapy in Latent Autoimmune Diabetes in Adults: Enhancing Glycemic Control and Preserving β-Cell Function

By MedXY|Jun 27, 2026

This study evaluates the clinical benefits of semaglutide, a GLP-1 receptor agonist, as an add-on therapy to insulin in patients with LADA, demonstrating improved glycemic control, BMI reduction, and insulin dose sparing, especially in thos

Comparative 1-Year Outcomes of Semaglutide, Tirzepatide, and Sleeve Gastrectomy in Obese Adults with Type 2 Diabetes: Insights from Real-World Data
Diabetes & Endocrinologyglycaemic controlobesity

Comparative 1-Year Outcomes of Semaglutide, Tirzepatide, and Sleeve Gastrectomy in Obese Adults with Type 2 Diabetes: Insights from Real-World Data

By MedXY|Jun 20, 2026

A retrospective cohort study evaluating 1-year weight loss, glycaemic control, and safety outcomes among adults with obesity and type 2 diabetes treated with semaglutide, tirzepatide, or sleeve gastrectomy, highlighting higher efficacy with

Semaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network Study
Diabetes & EndocrinologyGLP-1 receptor agonistneovascular age-related macular degeneration

Semaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network Study

By MedXY|Jun 10, 2026

In a large OHDSI network study of adults with type 2 diabetes, semaglutide was not associated with a higher or lower risk of neovascular age-related macular degeneration.

Cagrilintide-Semaglutide (CagriSema) Lowers HbA1c Better Than Semaglutide Alone in Type 2 Diabetes
Diabetes & EndocrinologycagrilintideHbA1c

Cagrilintide-Semaglutide (CagriSema) Lowers HbA1c Better Than Semaglutide Alone in Type 2 Diabetes

By MedXY|Jun 10, 2026

REIMAGINE 2 found that once-weekly cagrilintide-semaglutide lowered HbA1c more than semaglutide alone in adults with type 2 diabetes and overweight or obesity, with a safety profile consistent with known gastrointestinal effects.

CagriSema for Early Type 2 Diabetes: Interpreting the Phase 3a REIMAGINE 1 Trial in the Context of Incretin–Amylin Combination Therapy
Clinical UpdatescagrilintideCagriSema

CagriSema for Early Type 2 Diabetes: Interpreting the Phase 3a REIMAGINE 1 Trial in the Context of Incretin–Amylin Combination Therapy

By MedXY|Jun 9, 2026

REIMAGINE 1 shows that once-weekly CagriSema significantly reduced HbA1c and bodyweight versus placebo in early type 2 diabetes, with mainly gastrointestinal adverse events and a mechanistically compelling incretin–amylin profile.

No Signal for Increased Neovascular AMD Risk With Semaglutide in Adults With Type 2 Diabetes: Interpretation of a Large OHDSI Network Study
Diabetes & Endocrinologyneovascular age-related macular degenerationOHDSI

No Signal for Increased Neovascular AMD Risk With Semaglutide in Adults With Type 2 Diabetes: Interpretation of a Large OHDSI Network Study

By MedXY|Jun 4, 2026

A multinational OHDSI network analysis found no meaningful association between semaglutide use and neovascular age-related macular degeneration among adults with type 2 diabetes across cohort and self-controlled designs.

Semaglutide Improves Insulin Sensitivity in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial
Diabetes & Endocrinologyantipsychoticsinsulin sensitivity

Semaglutide Improves Insulin Sensitivity in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial

By MedXY|May 26, 2026

In a 30-week randomized trial, semaglutide improved insulin sensitivity, reduced insulin resistance, lowered fasting glucose, and produced substantial weight loss in patients with schizophrenia and prediabetes taking second-generation antip

Six-Week Native GIP Infusion Does Not Improve Glycaemic Control in Type 2 Diabetes, Alone or With Semaglutide
Diabetes & Endocrinologycontinuous glucose monitoringGIP

Six-Week Native GIP Infusion Does Not Improve Glycaemic Control in Type 2 Diabetes, Alone or With Semaglutide

By MedXY|May 26, 2026

A six-week native GIP infusion did not improve glucose control in type 2 diabetes, either alone or added to semaglutide, despite raising circulating GIP levels.

GLP-1 Weight-Loss and Diabetes Drugs: What Eye Specialists Say About NAION Risk
newsGLP-1 receptor agonistsNAION

GLP-1 Weight-Loss and Diabetes Drugs: What Eye Specialists Say About NAION Risk

By MedXY|May 18, 2026

A new consensus statement advises cautious, shared decision-making about GLP-1 receptor agonists and NAION risk, noting that current evidence is observational, conflicting, and suggests any absolute risk increase is small.

Semaglutide Reduced Effort Discounting and Improved Motivation Signals in Major Depressive Disorder
Diabetes & EndocrinologyGLP-1 receptor agonistmajor depressive disorder

Semaglutide Reduced Effort Discounting and Improved Motivation Signals in Major Depressive Disorder

By MedXY|May 5, 2026

In a 16-week randomized trial, adjunctive oral semaglutide improved effort-based decision-making in adults with major depressive disorder and overweight or obesity, suggesting a potential role for GLP-1 receptor agonism in reward-related dy

Semaglutide Shows Promise in Reducing Mental Illness Worsening in Patients with Depression and Anxiety, Swedish Study Finds
Diabetes & Endocrinologyanxietydepression

Semaglutide Shows Promise in Reducing Mental Illness Worsening in Patients with Depression and Anxiety, Swedish Study Finds

By MedXY|Apr 13, 2026

A landmark Swedish cohort study of 95,490 patients reveals that semaglutide is associated with a 42% lower risk of worsening mental illness in people with depression and anxiety, while other GLP-1 receptor agonists show varied effects. The

Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy: Synthesizing Evidence from Target Trial Emulations and Global Pharmacovigilance
Clinical UpdatesGLP-1 receptor agonistsNAION

Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy: Synthesizing Evidence from Target Trial Emulations and Global Pharmacovigilance

By MedXY|Apr 5, 2026

This review synthesizes recent evidence regarding the association between semaglutide initiation and nonarteritic anterior ischemic optic neuropathy (NAION), contrasting high-risk findings in real-world cohort studies with neutral findings

Is Semaglutide Worth the Cost? Evaluating the Economic Reality of GLP-1s for Heart Disease Prevention
Cardiologycardiovascular diseaseCost-Effectiveness

Is Semaglutide Worth the Cost? Evaluating the Economic Reality of GLP-1s for Heart Disease Prevention

By MedXY|Mar 20, 2026

A comprehensive simulation study evaluates the cost-effectiveness of semaglutide for secondary cardiovascular prevention in US adults without diabetes, finding significant health benefits but highlighting the need for price reductions to en

1 / 3
123
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities